<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931163</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008952</org_study_id>
    <secondary_id>IRB(2)#0513-0062</secondary_id>
    <secondary_id>CRAD001 JUST213</secondary_id>
    <nct_id>NCT01931163</nct_id>
  </id_info>
  <brief_title>NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer</brief_title>
  <acronym>NECTAR</acronym>
  <official_title>Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jenny C. Chang, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy&#xD;
      with Everolimus is in treating subjects with triple negative breast cancer who have residual&#xD;
      disease after chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II clinical trial of everolimus, an mTOR inhibitor, plus cisplatin&#xD;
      chemotherapy in patients with triple negative breast cancer (TNBC) who have residual disease&#xD;
      after completion of neoadjuvant chemotherapy. Everolimus and cisplatin will be administered&#xD;
      for 12 weeks. Patients will undergo surgery after treatment completion. Patients will have&#xD;
      breast biopsy prior to receiving the study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>tumor response at 12 weeks after treatment</time_frame>
    <description>Evaluate tumor response using RECIST criteria after 12 weeks of treatment at definitive surgery.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;, or similar definition that is accurate and appropriate.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>RAD001</other_name>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients ≥18 years of age.&#xD;
&#xD;
          2. Clinical/pathological documentation of residual disease after neo-adjuvant therapy.&#xD;
&#xD;
          3. Patients with synchronous bilateral cancers are eligible only if:&#xD;
&#xD;
             • Index cancer is triple-negative, defined as ER-, PR-, and HER2-.&#xD;
&#xD;
          4. HER2 negative tumors. HER2 negativity must be confirmed by one of the following:&#xD;
&#xD;
               -  FISH-negative (FISH ratio &lt;2.2), or&#xD;
&#xD;
               -  IHC 0-1+, or&#xD;
&#xD;
               -  IHC 2-3+ AND FISH-negative (FISH ratio &lt;2.2).&#xD;
&#xD;
          5. Estrogen receptor negative and progesterone receptor negative (&lt;10% staining by IHC&#xD;
             for estrogen receptor and progesterone receptor).&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          7. Adequate hematologic function, defined by:&#xD;
&#xD;
               -  Absolute neutrophil count 2 &gt;1000/mm3&#xD;
&#xD;
               -  Platelet count ≥100,000/mm3&#xD;
&#xD;
               -  Hemoglobin &gt;9 g/dL&#xD;
&#xD;
          8. Adequate liver function, defined by:&#xD;
&#xD;
               -  AST and ALT ≤2.5 x the upper limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x ULN (unless the patient has grade 1 bilirubin elevation&#xD;
                  due to Gilbert's disease or a similar syndrome involving slow conjugation of&#xD;
                  bilirubin).&#xD;
&#xD;
          9. Adequate renal function, defined by:&#xD;
&#xD;
             • Serum creatinine ≤1.5 x ULN&#xD;
&#xD;
         10. Complete staging work-up ≤24 weeks prior to initiation of study treatment with&#xD;
             computed tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis&#xD;
             preferred; abdomen accepted), a CT scan of the head or MRI of the brain (if&#xD;
             symptomatic), and either a positron emission tomography (PET) scan or a bone scan.&#xD;
&#xD;
         11. Adequate cardiac function, defined by a left ventricular ejection fraction (LVEF)&#xD;
             value of &gt;50% (or normal per institutional guidelines) by MUGA scan or echocardiogram&#xD;
             (ECHO).&#xD;
&#xD;
         12. Patients with previous history of invasive cancers (including breast cancer) are&#xD;
             eligible if definitive treatment was completed more than 5 years prior to initiating&#xD;
             current study treatment, and there is no evidence of recurrent disease.&#xD;
&#xD;
         13. Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             performed within 7 days prior to start of treatment. If a woman becomes pregnant or&#xD;
             suspects she is pregnant while participating in this study, she must agree to inform&#xD;
             her treating physician immediately.&#xD;
&#xD;
         14. Patient must be accessible for treatment and follow-up.&#xD;
&#xD;
         15. Women of childbearing potential must agree to use an acceptable method of birth&#xD;
             control to avoid pregnancy for the duration of study treatment, and for 3 months&#xD;
             thereafter.&#xD;
&#xD;
         16. Able to swallow and retain oral medication.&#xD;
&#xD;
         17. Patient must be willing to undergo breast biopsies as required by the study protocol.&#xD;
&#xD;
         18. All patients must be able to understand the investigational nature of the study and&#xD;
             give written informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          2. History of previously treated ductal carcinoma in situ (DCIS) is acceptable.&#xD;
&#xD;
          3. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel.&#xD;
&#xD;
          4. Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g.&#xD;
             sirolimus, temsirolimus);&#xD;
&#xD;
          5. Previous cancer (with the exception of non-melanoma skin cancer or cervical carcinoma&#xD;
             in situ) in the past 5 years.&#xD;
&#xD;
          6. Patients who have any severe and/or uncontrolled medical conditions such as:&#xD;
&#xD;
               1. unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction ≤6 months prior to start of Everolimus, serious uncontrolled cardiac&#xD;
                  arrhythmia, or any other clinically significant cardiac disease&#xD;
&#xD;
               2. Symptomatic congestive heart failure of New York heart Association Class III or&#xD;
                  IV&#xD;
&#xD;
               3. active (acute or chronic) or uncontrolled severe infection, liver disease such as&#xD;
                  cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable&#xD;
                  HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA),&#xD;
&#xD;
               4. known severely impaired lung function (spirometry and DLCO 50% or less of normal&#xD;
                  and O2 saturation 88% or less at rest on room air),&#xD;
&#xD;
               5. active, bleeding diathesis;&#xD;
&#xD;
          7. Patients may not receive any other investigational or anti-cancer treatments while&#xD;
             participating in this study.&#xD;
&#xD;
          8. Concurrent severe, uncontrolled infection or intercurrent illness including, but not&#xD;
             limited to, ongoing or active infection, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements.&#xD;
&#xD;
          9. Mental condition that would prevent patient comprehension of the nature of, and risk&#xD;
             associated with, the study.&#xD;
&#xD;
         10. Inability to comply with study and/or follow-up procedures.&#xD;
&#xD;
         11. Patients who have received live attenuated vaccines within 1 week of start of&#xD;
             Everolimus and during the study. Patient should also avoid close contact with others&#xD;
             who have received live attenuated vaccines.&#xD;
&#xD;
             Examples of live attenuated vaccines include intranasal influenza, measles, mumps,&#xD;
             rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines;&#xD;
&#xD;
         12. Known history of HIV seropositivity;&#xD;
&#xD;
         13. Women of child-bearing potential (WOCBP), defined as all women physiologically capable&#xD;
             of becoming pregnant, unless they are using highly effective methods of contraception&#xD;
             during dosing of study treatment. Highly effective contraception methods include&#xD;
             combination of any two of the following (a+b or a+c or b+c):&#xD;
&#xD;
               1. Use of oral, injected or implanted hormonal methods of contraception or;&#xD;
&#xD;
               2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);&#xD;
&#xD;
               3. Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;&#xD;
&#xD;
               4. Total abstinence or;&#xD;
&#xD;
               5. Male/female sterilization. Women are considered post-menopausal and not of&#xD;
                  child-bearing potential if they have had 12 months of natural (spontaneous)&#xD;
                  amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of&#xD;
                  vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without&#xD;
                  hysterectomy) or tubal ligation at least six weeks prior to treatment. In the&#xD;
                  case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
                  been confirmed by follow up hormone level assessment is she considered not of&#xD;
                  child-bearing potential.&#xD;
&#xD;
         14. Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or&#xD;
             inhaled corticosteroids are allowed;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Willowbrook</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 26, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <results_first_submitted>April 27, 2021</results_first_submitted>
  <results_first_submitted_qc>June 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2021</results_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>Jenny C. Chang, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator/Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT01931163/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>24 patients with Stage II/III Triple Negative Breast Cancer with residual cancer &gt;1cm post-neoadjuvant anthracycline and taxane-based chemotherapy were enrolled.&#xD;
Of the 24 patients, 2 were excluded (one because of metastasis before treatment and one because of withdrawal); 22 were included in the efficacy analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus Plus Cisplatin</title>
          <description>Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus Plus Cisplatin</title>
          <description>Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" lower_limit="31.9" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNBC patients with residual cancer &gt;1 cm post neoadjuvant anthracycline and chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>Evaluate tumor response using RECIST criteria after 12 weeks of treatment at definitive surgery.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;, or similar definition that is accurate and appropriate.</description>
        <time_frame>tumor response at 12 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus Plus Cisplatin</title>
            <description>Everolimus 10mg by mouth daily for 12 weeks; Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>Evaluate tumor response using RECIST criteria after 12 weeks of treatment at definitive surgery.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;, or similar definition that is accurate and appropriate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected during treatment period of 12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Everolimus Plus Cisplatin</title>
          <description>Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>leucocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>papilledema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jenny Chang</name_or_title>
      <organization>The Methodist Hospital Research Institute</organization>
      <phone>713 441-0680</phone>
      <email>jcchang@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

